MedChunk
Medically reviewed

Alopecia Areata JAK Inhibitors: Olumiant and Litfulo

Learn how Olumiant and Litfulo treat severe alopecia areata, including hair regrowth results, approved ages, doses, side effects, safety tests, and treatment choices.

By Caleb Bennett Reviewed by Dr. Irene Medical review dateNov 21, 2023 16 min read

Olumiant (baricitinib) and Litfulo (ritlecitinib) are prescription medicines that help some people with severe alopecia areata regrow their hair. Both are JAK inhibitors, which work by reducing immune system signals that contribute to hair loss. They are taken by mouth once daily and are approved in the United States for adults and adolescents aged 12 years and older with severe alopecia areata.

These medicines have made hair regrowth possible for some people who have experienced extensive hair loss. However, they do not work for everyone, and treatment requires careful medical monitoring because they can affect the immune system and cause potentially serious side effects.

How do JAK inhibitors help hair grow back?

Alopecia areata is an autoimmune condition. This means the immune system mistakenly attacks healthy parts of the body. In alopecia areata, immune cells target hair follicles, which are the structures in the skin that produce hair.

This immune activity interferes with normal hair growth and can cause patches of hair loss or more extensive loss across the scalp and body.

Janus kinase (JAK) proteins help carry signals between cells involved in immune activity. JAK inhibitors block certain signals that contribute to inflammation and immune attacks on hair follicles.

By reducing these signals, the medicines may allow affected follicles to resume hair growth. According to the National Alopecia Areata Foundation, JAK inhibitors are an important treatment option for severe alopecia areata, including forms involving complete scalp or body hair loss.

These medications control immune activity rather than permanently eliminating the condition. Hair loss may return if treatment is stopped.

Olumiant vs. Litfulo: What is the difference?

Olumiant and Litfulo have similar treatment goals but contain different active ingredients and affect somewhat different immune signaling pathways.

Olumiant (baricitinib)

Olumiant blocks JAK1 and JAK2, two proteins involved in immune signaling. It was the first oral JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) specifically for severe alopecia areata, initially receiving approval for adults in June 2022.

Its U.S. approval for severe alopecia areata was expanded in September 2026 to include adolescents aged 12 years and older.

Olumiant is available as an oral tablet. The recommended starting dose for severe alopecia areata is generally 2 mg once daily. A dermatologist may use 4 mg once daily when the response is inadequate or when hair loss is particularly extensive. After an adequate response to 4 mg, the prescribing information recommends reducing the dose to 2 mg daily.

According to the U.S. National Library of Medicine's DailyMed prescribing information for Olumiant, dosing also depends on factors such as kidney function, blood cell counts, and other medications.

Litfulo (ritlecitinib)

Litfulo was approved by the FDA in June 2023 for severe alopecia areata in people aged 12 years and older.

It works by inhibiting JAK3 and a group of enzymes called TEC family kinases. These proteins participate in immune cell signaling.

Litfulo comes as a 50 mg capsule taken once daily. Unlike Olumiant, which has more than one commonly used dose for alopecia areata, Litfulo has a recommended daily dose of 50 mg.

The capsule should be swallowed whole. It should not be crushed, split, or chewed.

Quick comparison

Feature Olumiant Litfulo
Active ingredient Baricitinib Ritlecitinib
Main targets JAK1 and JAK2 JAK3 and TEC family kinases
U.S. approval for alopecia areata 2022; expanded to ages 12+ in 2026 2023
Approved age 12 years and older 12 years and older
Usual dose 2 mg daily, sometimes 4 mg daily 50 mg daily
Form Tablet Capsule
Main purpose Treat severe alopecia areata Treat severe alopecia areata

Both medicines are systemic treatments, meaning they work throughout the body rather than only on the scalp.

How effective are Olumiant and Litfulo for hair regrowth?

Clinical trials have shown meaningful hair regrowth in some patients taking either medication. However, the likelihood and amount of regrowth differ between individuals.

Researchers often measure treatment response using the Severity of Alopecia Tool (SALT). This measures the percentage of scalp hair that has been lost. A SALT score of 20 or less means that no more than 20% of scalp hair is missing.

Hair regrowth results with Olumiant

Two major clinical trials evaluated Olumiant in adults with severe alopecia areata who had lost at least half of their scalp hair.

At 36 weeks:

  • Approximately 32% to 35% of participants receiving 4 mg daily achieved at least 80% scalp hair coverage.
  • Approximately 17% to 22% receiving 2 mg daily reached the same level of coverage.
  • Only about 3% to 5% receiving a placebo achieved this result.

Some participants also experienced improvement in eyebrow and eyelash hair growth.

These findings suggest that the 4 mg dose may produce a stronger scalp hair response in some patients. However, a higher dose can also affect the balance of benefits and risks. Dose selection should always be made by the prescribing clinician.

Hair regrowth results with Litfulo

Litfulo was studied in adolescents and adults with severe alopecia areata.

After 24 weeks of treatment with 50 mg daily:

  • 23% of participants had 20% or less scalp hair loss remaining.
  • 13.4% had 10% or less scalp hair loss remaining.
  • Among participants receiving a placebo, 1.6% and 1.5%, respectively, achieved these outcomes.

The DailyMed prescribing information for Litfulo provides these results from its controlled clinical trial.

These findings show that Litfulo can promote substantial regrowth in a proportion of patients, although some people may need longer treatment before meaningful improvement becomes apparent.

Is Olumiant more effective than Litfulo?

It is not possible to conclude from these trial percentages alone that one medicine is better than the other.

The drugs were studied in different clinical trials, with different participant groups, study designs, and primary assessment times. Olumiant's major adult trials evaluated the main response at 36 weeks, while Litfulo's pivotal trial evaluated it at 24 weeks.

A dermatologist can compare the available evidence with an individual's age, extent of hair loss, medical history, and treatment priorities.

How long does it take for JAK inhibitors to work?

Hair regrowth with Olumiant or Litfulo is generally a gradual process. These medicines should not be expected to restore a full head of hair within a few weeks.

Some people may notice new hair growth during the first several months. Others may need six months or longer to experience a substantial change.

In clinical trials, meaningful scalp hair responses were assessed at approximately six months for Litfulo and nine months for Olumiant. Continued treatment may produce additional improvement in some patients.

Dermatologists commonly evaluate progress by examining the scalp, comparing photographs, and measuring changes in scalp hair coverage. Eyebrow and eyelash growth may also be reviewed when relevant.

Limited improvement early in treatment does not necessarily mean that a medicine will never work. However, treatment should be reviewed at appropriate intervals to determine whether continuing it is worthwhile.

Who may be a candidate for Olumiant or Litfulo?

These medications are primarily intended for people with severe alopecia areata, rather than every type of hair thinning or hair loss.

A dermatologist may consider a JAK inhibitor when alopecia areata affects a substantial area of the scalp, causes extensive ongoing hair loss, or has not responded adequately to other suitable treatments.

Severe forms can include alopecia totalis, which involves loss of all scalp hair, and alopecia universalis, which involves loss of hair across the body.

The American Academy of Dermatology explains that treatment decisions depend on factors such as the amount of hair loss, the patient's age, and the areas affected.

For people with only a few smaller patches of hair loss, a dermatologist may consider treatments such as corticosteroid injections or topical medicines instead.

Can teenagers take these medicines?

Under current U.S. FDA labeling, both Olumiant and Litfulo may be prescribed for severe alopecia areata starting at age 12.

Neither is approved for alopecia areata in children younger than 12 years.

Age eligibility does not mean that either medicine is automatically suitable for every adolescent. A specialist must assess treatment benefits, medical history, infection risks, and monitoring requirements.

Regulatory approval and availability may differ between countries.

What are the common side effects?

Both treatments affect immune signaling throughout the body. Some side effects are relatively minor and manageable, while others require prompt medical evaluation.

Possible side effects of Olumiant

Side effects reported during alopecia areata trials include:

  • Upper respiratory tract infections
  • Headache
  • Acne
  • Urinary tract infections
  • Nausea or abdominal discomfort
  • Increased cholesterol levels
  • Changes in liver enzyme levels
  • Inflammation around hair follicles
  • Fatigue

Some patients also experience changes in blood cell counts or other laboratory results.

Possible side effects of Litfulo

Reported side effects include:

  • Headache
  • Diarrhea
  • Acne
  • Rash or hives
  • Folliculitis
  • Fever
  • Dizziness
  • Certain respiratory or other infections

Not everyone experiences these effects. Their frequency and importance depend on the particular medicine and the patient's health circumstances.

What serious risks should patients know about?

Olumiant and Litfulo carry FDA boxed warnings, the agency's most prominent type of prescription drug safety warning.

These warnings address potentially serious complications, including infections, cancer, major cardiovascular events, blood clots, and an increased risk of death observed in certain JAK inhibitor safety studies.

According to the American Academy of Dermatology's guidance on JAK inhibitors, some serious warnings are based partly on findings involving other medicines in the same drug class. This is important when interpreting an individual medication's safety information.

Serious infections

JAK inhibitors can reduce the immune system's ability to fight certain infections.

Potential concerns include tuberculosis, shingles, and serious bacterial, fungal, or viral infections.

Patients should contact their healthcare team promptly if they develop concerning symptoms such as persistent fever, worsening cough, unusual weakness, or other signs of infection while receiving treatment.

Blood clots and cardiovascular events

Blood clots in the legs or lungs and major cardiovascular events, such as heart attack or stroke, are important safety concerns associated with this class of medicines.

These risks require particular consideration in people with a history of blood clots, cardiovascular disease, smoking, or other relevant risk factors.

Sudden chest pain, severe difficulty breathing, new one-sided weakness, or sudden speech difficulties require emergency medical attention.

Cancer-related warnings

Malignancies have been reported among patients treated with JAK inhibitors. Some of the broader class warnings reflect evidence from studies of another JAK inhibitor in patients with rheumatoid arthritis.

A history of cancer or other relevant risk factors should be discussed with the prescribing clinician before treatment.

The presence of a boxed warning does not mean every patient will develop a serious complication. It means the potential risks are important enough to require careful assessment and monitoring.

What tests are needed before starting treatment?

A dermatologist usually reviews medical history, current medicines, possible infections, vaccination history, and baseline laboratory results before prescribing a JAK inhibitor.

Depending on the medicine, this evaluation may include:

  • Tuberculosis screening: To check for active or latent tuberculosis infection.
  • Hepatitis screening: To identify certain viral infections that could affect treatment safety.
  • Complete blood count: To assess white blood cells, platelets, and other blood measurements.
  • Liver function tests: To identify relevant liver abnormalities.
  • Kidney function assessment: Particularly important for Olumiant dosing and suitability.
  • Cholesterol testing: Especially relevant during monitoring with Olumiant.
  • Vaccination review: To address recommended immunizations before treatment when appropriate.

Repeat blood tests may be needed during therapy. The schedule and specific tests differ between Olumiant and Litfulo.

Live vaccines are generally avoided during treatment with these medicines. Patients should discuss vaccination timing with their healthcare professional.

When might these medicines not be suitable?

Certain health conditions and circumstances can make JAK inhibitor treatment less appropriate or require extra precautions.

Important considerations include:

  • An active serious infection
  • Untreated tuberculosis
  • Significant abnormalities in certain blood cell counts
  • Relevant liver or kidney disease
  • A history of blood clots or major cardiovascular events
  • Certain cancers or cancer risk factors
  • Pregnancy, plans for pregnancy, or breastfeeding
  • Use of medicines that may interact with a JAK inhibitor

These considerations are not identical for both medicines. For example, Olumiant has specific restrictions and dose adjustments related to kidney function, while Litfulo has its own blood count requirements and drug interaction precautions.

Both medicines are generally not recommended in combination with other JAK inhibitors or certain powerful immune-suppressing treatments.

Pregnancy and breastfeeding require specific counseling because the medicines may present risks to a developing baby or nursing infant. The product-specific prescribing information should guide these discussions.

Will hair fall out again after stopping a JAK inhibitor?

Hair loss can return after Olumiant or Litfulo is discontinued.

Alopecia areata is a condition that can remain active over time. Although JAK inhibitors may control the immune activity associated with hair loss, they are not considered permanent cures.

Some people may need continued treatment to maintain their results. Others may stop therapy because of side effects, limited improvement, changes in health, or other medical considerations.

Decisions about continuing, adjusting, or discontinuing medication should be made with the prescribing dermatologist. Patients should not change doses or restart treatment independently.

How do dermatologists choose between Olumiant and Litfulo?

Choosing a JAK inhibitor involves more than comparing clinical trial response percentages.

A dermatologist will generally consider the extent and duration of hair loss, age, previous treatments, other medical conditions, potential drug interactions, and the patient's preferences.

Factors that may influence the choice

Age and approval: Both are FDA-approved for severe alopecia areata in people aged 12 and older.

Medical history: Kidney function, liver health, infection history, and cardiovascular risk may affect suitability.

Dosing: Olumiant has an adjustable dose regimen, while Litfulo is normally prescribed at 50 mg daily.

Treatment response: Clinical evidence can help establish reasonable expectations, although no individual response can be guaranteed.

Access and cost: Insurance coverage, local regulatory approvals, and patient assistance programs may influence which treatment is accessible.

Safety monitoring: Both require follow-up, but some monitoring details differ.

Neither medicine should automatically be considered the best option for every person with severe alopecia areata.

Are Olumiant and Litfulo the only JAK inhibitors for alopecia areata?

No. Another oral JAK inhibitor, Leqselvi (deuruxolitinib), received U.S. FDA approval in 2024 for adults with severe alopecia areata.

Unlike Olumiant and Litfulo, Leqselvi is approved for adults aged 18 and older and is taken twice daily.

Some other JAK inhibitors have been investigated or used off-label for alopecia areata. However, treatment evidence, regulatory approval, and safety requirements differ among individual medicines.

The availability of several JAK inhibitors gives dermatologists more options when developing a treatment plan.

What should you discuss with your dermatologist?

Before beginning Olumiant or Litfulo, it is useful to understand the expected benefits, possible risks, and practical requirements of treatment.

Questions worth discussing include how much hair regrowth is a realistic goal, when treatment progress will be reviewed, what blood tests are required, and which symptoms should prompt medical attention.

Patients should also explain whether they take other prescription medicines or supplements, have experienced serious infections, or are pregnant, breastfeeding, or planning pregnancy.

Photographs and regular scalp examinations can help track progress more consistently than relying on daily impressions of hair growth.

The bottom line

Olumiant and Litfulo are important oral treatment options for severe alopecia areata. Both help reduce immune signals involved in hair loss, and clinical trials show that some patients can achieve substantial scalp hair regrowth.

Olumiant offers different dosing options, while Litfulo uses a standard once-daily capsule. Both are approved in the United States for patients aged 12 and older.

Because these treatments carry meaningful safety risks and may require long-term use, choosing between them should involve a dermatologist who can assess likely benefits, medical history, laboratory results, and treatment preferences.

Frequently Asked Questions

Common questions about Olumiant, Litfulo, and JAK inhibitor treatment for alopecia areata.

Can Olumiant or Litfulo regrow all my hair?

Some patients experience extensive hair regrowth with these medicines, but complete regrowth is not guaranteed. Clinical trials show that a proportion of patients achieve 80% or more scalp hair coverage. Results depend on treatment response and other individual factors.

Can a 12-year-old take Olumiant or Litfulo?

Yes. Under current U.S. FDA labeling, both medicines are approved for severe alopecia areata in patients aged 12 years and older. A dermatologist must determine whether treatment is appropriate and arrange the necessary safety monitoring.

Do I need to take JAK inhibitors forever for alopecia areata?

Some people may need ongoing treatment to maintain hair regrowth because alopecia areata can become active again after medication is stopped. The appropriate duration depends on treatment response, side effects, and clinical follow-up. These medicines are not considered permanent cures.

Can Olumiant and Litfulo be taken together?

No. Their prescribing information does not recommend combining them with other JAK inhibitors. Using both could increase immune suppression and safety concerns without an established additional benefit. A dermatologist should direct any change from one medication to another.

Are JAK inhibitors better than steroid injections for alopecia areata?

They serve different treatment needs. Steroid injections are often considered for limited patches of alopecia areata, while oral JAK inhibitors are important options for severe or extensive hair loss. The best approach depends on the pattern of hair loss, age, previous treatment response, and overall health.

Citations

  1. National Alopecia Areata Foundation — FDA-Approved JAK Inhibitors
  2. U.S. National Library of Medicine, DailyMed — Olumiant (Baricitinib) Prescribing Information
  3. U.S. National Library of Medicine, DailyMed — Litfulo (Ritlecitinib) Prescribing Information
  4. American Academy of Dermatology — Alopecia Areata: Diagnosis and Treatment
  5. American Academy of Dermatology — JAK Inhibitors: What Your Dermatologist Wants You to Know
Share this article